CLINICAL_TRIALS
trial_result
· 2012-01-26
Clinical Trial Update: Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease [Phase 3]
Summary
Phase 3 trial evaluating paricalcitol for reducing serum intact parathyroid hormone in chronic kidney disease; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Abbott | Conditions: Chronic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2012-01-26